(From
left
to
right)
Dr
Joseph
Chan,
Chief
Medical
Officer
of
HKSH
Medical
Group
and
Deputy
Medical
Superintendent
of
Hong
Kong
Sanatorium
&
Hospital;
Ken
Lau,
Managing
Director
of
Greater
China
and
Hong
Kong
Chief
Executive
Officer,
FWD;
and
Ronald
Lo,
General
Manager
of
Roche
Diagnostics
(Hong
Kong)
Limited,
jointly
announced
a
collaboration
to
enhance
public
awareness
of
Comprehensive
Genomic
Profiling
and
related
health
information.
New
trends
in
precision
medicine:
jointly
enhancing
public
awareness
Cancer treatment is advancing rapidly, with precision medicine emerging as a key direction for development. Among these advancements, Comprehensive Genomic Profiling (CGP) can analyse multiple cancer types simultaneously, delving into the genomic alterations of a patient’s tumour to formulate more precise and personalised treatment plans. This technology helps doctors accurately match patients with targeted therapies and monitor genomic changes during tumour resistance, recurrence, and metastasis to adjust treatment strategies, thereby improving patient outcome.
Through FWD MAX, FWD will publish a series of cancer-related content, including the latest developments in CGP and precision medicine, aiming to increase public awareness and improve understanding of cancer and precision medicine. Oncologists from HKSH Cancer Centre will also share knowledge of cancer precision medicine on FWD MAX, further enhancing public understanding of CGP.
Beyond insurance: FWD expands healthcare partner network to strengthen professional health support
Ken Lau, Managing Director of Greater China and Hong Kong Chief Executive Officer, FWD, said, “FWD is committed to collaborating with medical institutions to provide the public with more comprehensive and forward-looking health protection and support services, covering prevention, treatment, and recovery. As cancer becomes increasingly prevalent and poses a major health challenge in Hong Kong, we are pleased to partner with Roche Diagnostics and HKSH Cancer Centre to enhance public awareness of CGP, an advanced diagnostic technology. Through FWD MAX, the public will have access to reliable information on cancer treatment technologies and healthcare content, supporting them in navigating cancer risks.”
Ronald Lo, General Manager of Roche Diagnostics (Hong Kong) Limited, said, “Roche Diagnostics is committed to leveraging innovative medical technology to explore more advanced diagnostic methods for cancer patients. We are honoured to partner with FWD and HKSH Cancer Centre. Through promoting Comprehensive Genomic Profiling, we hope to enhance public understanding of precision medicine in Hong Kong, enabling more patients to receive appropriate treatment and have more choices and better treatment outcomes on their anti-cancer journey.²”
HKSH Cancer Centre’s genetic testing guides personalised precision treatment
HKSH Cancer Centre is currently the only private medical institution in Hong Kong offering in-house CGP testing with the entire process from tissue sampling, laboratory testing to data analysis conducted on-site. In-house CGP test enables the detection of mutations in over 300 cancer-related genes in a single assay without the need to send samples to overseas laboratories, significantly shortening turnaround time. HKSH’s dedicated pathology team can also provide reports with a clear and in-depth narrative offering specific guidance for doctors to formulate timely and targeted treatment strategies, maximising the potential for personalised and precise cancer care.
Dr Joseph Chan, Chief Medical Officer of HKSH Medical Group and Deputy Medical Superintendent of Hong Kong Sanatorium & Hospital, said, “HKSH Cancer Centre strives to provide patients with comprehensive one-stop services for cancer screening, diagnosis, treatment and rehabilitation. In addition to a top-notch medical team, HKSH is also equipped with cutting-edge medical technologies, such as the first proton therapy system in the Greater Bay Area and we are also Hong Kong’s only private medical institution offering in-house CGP service. We believe that CGP is the key to achieving precise and personalised cancer management. Based on genetic test results and patient conditions, doctors can provide critical analysis at the time of cancer diagnosis, relapse, or metastasis, thus formulating highly effective and personalised treatment plans. Whether patients need to undergo surgery, chemotherapy, proton therapy, stereotactic radiotherapy, targeted therapy, hormonal therapy, cellular therapy, or immunotherapy, our multidisciplinary medical team will provide the most comprehensive and compassionate support throughout the treatment and recovery process.”
[1]
The
Hong
Kong
Cancer
Registry
of
the
Hospital
Authority,
“Overview
of
Cancer
Statistics
in
Hong
Kong,
2022”
[2]
For
informational
use
only;
this
is
not
a
substitute
for
professional
medical
advice.
Please
consult
your
doctor
or
qualified
healthcare
provider
for
any
health
concerns.
Hashtag: #FWD
The issuer is solely responsible for the content of this announcement.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate